Browsing Tag
JAK2V617F
1 post
Is mutant-selective JAK2 inhibition ready for clinical reality after Prelude Therapeutics’ FDA IND clearance?
Prelude Therapeutics gains FDA IND clearance for PRT12396. Read how mutant-selective JAK2 inhibition could reshape MPN drug development.